Valary Lab is an API manufacturer based in India. It holds 50 active US drug master files across a filed portfolio of 17 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 13 September 2024 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Anakapalli District, India | 3019200343 |
| Molecule | Regulators | Docs |
|---|---|---|
| Belzutifan | US FDA | 3 |
| Binimetinib | US FDA | 3 |
| Cabozantinib | US FDA | 3 |
| Desogestrel | US FDA | 3 |
| Encorafenib | US FDA | 3 |
| Ethinylestradiol | US FDA | 3 |
| Lenalidomide | US FDA | 3 |
| Levonorgestrel | US FDA | 3 |
| Levothyroxine | US FDA | 3 |
| Liothyronine Sodium | US FDA | 3 |
| Niraparib | US FDA | 3 |
| Pralsetinib | US FDA | 3 |
| Ribociclib | US FDA | 3 |
| Ruxolitinib | US FDA | 3 |
| Tivozanib | US FDA | 3 |
| Trametinib | US FDA | 3 |
| Dabrafenib | US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Valary Lab comes back tiered against every other supplier able to file there.
Start for free